Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Net Cash Flow (2018 - 2025)

Exagen (XGN) has disclosed Net Cash Flow for 8 consecutive years, with -$3.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 343300.0% year-over-year to -$3.4 million, compared with a TTM value of $10.2 million through Dec 2025, up 170.44%, and an annual FY2025 reading of $10.2 million, up 170.44% over the prior year.
  • Net Cash Flow was -$3.4 million for Q4 2025 at Exagen, down from $5.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $60.6 million in Q1 2021 and bottomed at -$20.7 million in Q2 2023.
  • Average Net Cash Flow over 5 years is -$1.3 million, with a median of -$5.6 million recorded in 2021.
  • The sharpest move saw Net Cash Flow skyrocketed 1863.74% in 2021, then plummeted 343300.0% in 2025.
  • Year by year, Net Cash Flow stood at -$7.3 million in 2021, then increased by 13.8% to -$6.3 million in 2022, then soared by 227.44% to $8.0 million in 2023, then tumbled by 99.99% to $1000.0 in 2024, then tumbled by 343300.0% to -$3.4 million in 2025.
  • Business Quant data shows Net Cash Flow for XGN at -$3.4 million in Q4 2025, $5.6 million in Q3 2025, and $18.8 million in Q2 2025.